Sign in to edit your profile (add interests, mentoring, photo, etc.)

    George Sakoulas

    TitleAssociate Adjunct Professor
    SchoolUniversity of California, San Diego
    Address9500 Gilman Drive #0687
    CA La Jolla 92093
    vCardDownload vCard

      Collapse Research 
      Collapse Research Activities and Funding
      Developmental and Translational Pharmacology of Pediatric Antimicrobial Therapy
      NIH/NICHD U54HD071600Sep 26, 2011 - Jun 30, 2016
      Role: Co-Investigator

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Rose WE, Shukla SK, Berti AD, Hayney MS, Henriquez KM, Ranzoni A, Cooper MA, Proctor RA, Nizet V, Sakoulas G. Increased Endovascular Staphylococcus aureus Inoculum Is the Link Between Elevated Serum Interleukin 10 Concentrations and Mortality in Patients With Bacteremia. Clin Infect Dis. 2017 May 15; 64(10):1406-1412. PMID: 28205673.
        View in: PubMed
      2. Caffrey AR, Timbrook TT, Noh E, Sakoulas G, Opal SM, Nizet V, LaPlante KL. Evidence To Support Continuation of Statin Therapy in Patients with Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother. 2017 Mar; 61(3). PMID: 28069650.
        View in: PubMed
      3. Sakoulas G, Rose W, Berti A, Olson J, Munguia J, Nonejuie P, Sakoulas E, Rybak MJ, Pogliano J, Nizet V. Classical ß-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii. Antimicrob Agents Chemother. 2017 Feb; 61(2). PMID: 27872080.
        View in: PubMed
      4. Henson KE, Yim J, Smith JR, Sakoulas G, Rybak MJ. ß-Lactamase Inhibitors Enhance the Synergy between ß-Lactam Antibiotics and Daptomycin against Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2017 Jan; 61(1). PMID: 27821441.
        View in: PubMed
      5. Sakoulas G, Olson J, Yim J, Singh NB, Kumaraswamy M, Quach DT, Rybak MJ, Pogliano J, Nizet V. Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother. 2016 Nov; 60(11):6609-6618. PMID: 27572414.
        View in: PubMed
      6. Le J, Dam Q, Schweizer M, Thienphrapa W, Nizet V, Sakoulas G. Effects of vancomycin versus nafcillin in enhancing killing of methicillin-susceptible Staphylococcus aureus causing bacteremia by human cathelicidin LL-37. Eur J Clin Microbiol Infect Dis. 2016 Sep; 35(9):1441-7. PMID: 27234592; PMCID: PMC4983239 [Available on 09/01/17].
      7. Werth BJ, Smith JR, Sakoulas G. New Guidelines Endorse Old Recommendations for Invasive Enterococcal Infections. Clin Infect Dis. 2016 Jul 15; 63(2):281-2. PMID: 27161781.
        View in: PubMed
      8. Huntington JA, Sakoulas G, Umeh O, Cloutier DJ, Steenbergen JN, Bliss C, Goldstein EJ. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial. J Antimicrob Chemother. 2016 Jul; 71(7):2014-21. PMID: 26994090.
        View in: PubMed
      9. Kumaraswamy M, Lin L, Olson J, Sun CF, Nonejuie P, Corriden R, Döhrmann S, Ali SR, Amaro D, Rohde M, Pogliano J, Sakoulas G, Nizet V. Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR Stenotrophomonas maltophilia. J Antimicrob Chemother. 2016 May; 71(5):1264-9. PMID: 26832758; PMCID: PMC4830416 [Available on 05/01/17].
      10. Quach DT, Sakoulas G, Nizet V, Pogliano J, Pogliano K. Bacterial Cytological Profiling (BCP) as a Rapid and Accurate Antimicrobial Susceptibility Testing Method for Staphylococcus aureus. EBioMedicine. 2016 Feb; 4:95-103. PMID: 26981574; PMCID: PMC4776060.
      11. Kullar R, Sakoulas G, Deresinski S, van Hal SJ. When sepsis persists: a review of MRSA bacteraemia salvage therapy. J Antimicrob Chemother. 2016 Mar; 71(3):576-86. PMID: 26565015.
        View in: PubMed
      12. Berti AD, Theisen E, Sauer JD, Nonejuie P, Olson J, Pogliano J, Sakoulas G, Nizet V, Proctor RA, Rose WE. Penicillin Binding Protein 1 Is Important in the Compensatory Response of Staphylococcus aureus to Daptomycin-Induced Membrane Damage and Is a Potential Target for ß-Lactam-Daptomycin Synergy. Antimicrob Agents Chemother. 2015 Nov 02; 60(1):451-8. PMID: 26525797; PMCID: PMC4704217.
      13. Sakoulas G, Kumaraswamy M, Nonejuie P, Werth BJ, Rybak MJ, Pogliano J, Rice LB, Nizet V. Differential Effects of Penicillin Binding Protein Deletion on the Susceptibility of Enterococcus faecium to Cationic Peptide Antibiotics. Antimicrob Agents Chemother. 2015 Oct; 59(10):6132-9. PMID: 26195528; PMCID: PMC4576044.
      14. Lin L, Nonejuie P, Munguia J, Hollands A, Olson J, Dam Q, Kumaraswamy M, Rivera H, Corriden R, Rohde M, Hensler ME, Burkart MD, Pogliano J, Sakoulas G, Nizet V. Azithromycin Synergizes with Cationic Antimicrobial Peptides to Exert Bactericidal and Therapeutic Activity Against Highly Multidrug-Resistant Gram-Negative Bacterial Pathogens. EBioMedicine. 2015 Jul; 2(7):690-8. PMID: 26288841; PMCID: PMC4534682.
      15. Varada NL, Sakoulas G, Lei LR, Chua J. Agranulocytosis with ceftaroline high-dose monotherapy or combination therapy with clindamycin. Pharmacotherapy. 2015 Jun; 35(6):608-12. PMID: 26037689.
        View in: PubMed
      16. Moise PA, Sakoulas G, McKinnell JA, Lamp KC, DePestel DD, Yoon MJ, Reyes K, Zervos MJ. Clinical Outcomes of Daptomycin for Vancomycin-resistant Enterococcus Bacteremia. Clin Ther. 2015 Jul 01; 37(7):1443-1453.e2. PMID: 25982687.
        View in: PubMed
      17. Hindler JA, Wong-Beringer A, Charlton CL, Miller SA, Kelesidis T, Carvalho M, Sakoulas G, Nonejuie P, Pogliano J, Nizet V, Humphries R. In vitro activity of daptomycin in combination with ß-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci. Antimicrob Agents Chemother. 2015 Jul; 59(7):4279-88. PMID: 25963982; PMCID: PMC4468720.
      18. Moise PA, Sakoulas G. Staphylococcus aureus bacteraemia management: where do we stand and where are we going? Evid Based Med. 2015 Aug; 20(4):126. PMID: 25895528.
        View in: PubMed
      19. Berti AD, Baines SL, Howden BP, Sakoulas G, Nizet V, Proctor RA, Rose WE. Heterogeneity of genetic pathways toward daptomycin nonsusceptibility in Staphylococcus aureus determined by adjunctive antibiotics. Antimicrob Agents Chemother. 2015 May; 59(5):2799-806. PMID: 25733508; PMCID: PMC4394801.
      20. Smith JR, Barber KE, Raut A, Aboutaleb M, Sakoulas G, Rybak MJ. ß-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother. 2015; 70(6):1738-43. PMID: 25645208; PMCID: PMC4542582.
      21. Sakoulas G, Nonejuie P, Kullar R, Pogliano J, Rybak MJ, Nizet V. Examining the use of ceftaroline in the treatment of Streptococcus pneumoniae meningitis with reference to human cathelicidin LL-37. Antimicrob Agents Chemother. 2015 Apr; 59(4):2428-31. PMID: 25605351; PMCID: PMC4356754.
      22. Hall Snyder A, Werth BJ, Barber KE, Sakoulas G, Rybak MJ. Comment on: Failure of combination therapy with daptomycin and synergistic ceftriaxone for enterococcal endocarditis. J Antimicrob Chemother. 2015 Apr; 70(4):1272-3. PMID: 25433012.
        View in: PubMed
      23. Kullar R, McKinnell JA, Sakoulas G. Reply to Eschenauer et al. Clin Infect Dis. 2015 Feb 15; 60(4):671-2. PMID: 25371486; PMCID: PMC4809982.
      24. Werth BJ, Barber KE, Tran KN, Nonejuie P, Sakoulas G, Pogliano J, Rybak MJ. Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE. J Antimicrob Chemother. 2015 Feb; 70(2):489-93. PMID: 25304643.
        View in: PubMed
      25. Bayer AS, Mishra NN, Sakoulas G, Nonejuie P, Nast CC, Pogliano J, Chen KT, Ellison SN, Yeaman MR, Yang SJ. Heterogeneity of mprF sequences in methicillin-resistant Staphylococcus aureus clinical isolates: role in cross-resistance between daptomycin and host defense antimicrobial peptides. Antimicrob Agents Chemother. 2014 Dec; 58(12):7462-7. PMID: 25288091; PMCID: PMC4249560.
      26. Dhand A, Sakoulas G. Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia. Clin Ther. 2014 Oct 01; 36(10):1303-16. PMID: 25444563.
        View in: PubMed
      27. Barber KE, Rybak MJ, Sakoulas G. Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia. J Antimicrob Chemother. 2015 Jan; 70(1):311-3. PMID: 25125677.
        View in: PubMed
      28. Kullar R, McKinnell JA, Sakoulas G. Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy. Clin Infect Dis. 2014 Nov 15; 59(10):1455-61. PMID: 25048852; PMCID: PMC4215066.
      29. Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, Rybak MJ, Kullar R, Dhand A, Rose WE, Goff DA, Bressler AM, Lee Y, Pogliano J, Johns S, Kaatz GW, Ebright JR, Nizet V. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther. 2014 Oct 01; 36(10):1317-33. PMID: 25017183.
        View in: PubMed
      30. Barber KE, Werth BJ, Ireland CE, Stone NE, Nonejuie P, Sakoulas G, Pogliano J, Rybak MJ. Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes. J Antimicrob Chemother. 2014 Nov; 69(11):3006-10. PMID: 24990867.
        View in: PubMed
      31. Werth BJ, Steed ME, Ireland CE, Tran TT, Nonejuie P, Murray BE, Rose WE, Sakoulas G, Pogliano J, Arias CA, Rybak MJ. Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis. Antimicrob Agents Chemother. 2014 Sep; 58(9):5253-61. PMID: 24957825; PMCID: PMC4135850.
      32. Hall Snyder A, Werth BJ, Barber KE, Sakoulas G, Rybak MJ. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. J Antimicrob Chemother. 2014 Aug; 69(8):2148-54. PMID: 24777900.
        View in: PubMed
      33. Kullar R, McClellan I, Geriak M, Sakoulas G. Efficacy and safety of daptomycin in patients with renal impairment: a multicenter retrospective analysis. Pharmacotherapy. 2014 Jun; 34(6):582-9. PMID: 24658897.
        View in: PubMed
      34. Sakoulas G, Guram K, Reyes K, Nizet V, Zervos M. Human cathelicidin LL-37 resistance and increased daptomycin MIC in methicillin-resistant Staphylococcus aureus strain USA600 (ST45) are associated with increased mortality in a hospital setting. J Clin Microbiol. 2014 Jun; 52(6):2172-4. PMID: 24648548; PMCID: PMC4042812.
      35. Sakoulas G, Rose W, Nonejuie P, Olson J, Pogliano J, Humphries R, Nizet V. Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 2014; 58(3):1494-500. PMID: 24366742; PMCID: PMC3957885.
      36. Sakoulas G, Okumura CY, Thienphrapa W, Olson J, Nonejuie P, Dam Q, Dhand A, Pogliano J, Yeaman MR, Hensler ME, Bayer AS, Nizet V. Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus. J Mol Med (Berl). 2014 Feb; 92(2):139-49. PMID: 24297496; PMCID: PMC3926703.
      37. Ortwine JK, Werth BJ, Sakoulas G, Rybak MJ. Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the "seesaw effect": Taking advantage of the back door left open? Drug Resist Updat. 2013 Jul-Nov; 16(3-5):73-9. PMID: 24268586.
        View in: PubMed
      38. Humphries RM, Pollett S, Sakoulas G. A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev. 2013 Oct; 26(4):759-80. PMID: 24092854; PMCID: PMC3811228.
      39. Calderwood MS, Desjardins CA, Sakoulas G, Nicol R, Dubois A, Delaney ML, Kleinman K, Cosimi LA, Feldgarden M, Onderdonk AB, Birren BW, Platt R, Huang SS. Staphylococcal enterotoxin P predicts bacteremia in hospitalized patients colonized with methicillin-resistant Staphylococcus aureus. J Infect Dis. 2014 Feb 15; 209(4):571-7. PMID: 24041793; PMCID: PMC3903375.
      40. Kullar R, Casapao AM, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother. 2013 Dec; 68(12):2921-6. PMID: 23928022; PMCID: PMC3820108.
      41. Berti AD, Sakoulas G, Nizet V, Tewhey R, Rose WE. ß-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2013 Oct; 57(10):5005-12. PMID: 23896478; PMCID: PMC3811465.
      42. Casapao AM, Kullar R, Davis SL, Levine DP, Zhao JJ, Potoski BA, Goff DA, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Antimicrob Agents Chemother. 2013 Sep; 57(9):4190-6. PMID: 23774437; PMCID: PMC3754344.
      43. Sakoulas G, Nonejuie P, Nizet V, Pogliano J, Crum-Cianflone N, Haddad F. Treatment of high-level gentamicin-resistant Enterococcus faecalis endocarditis with daptomycin plus ceftaroline. Antimicrob Agents Chemother. 2013 Aug; 57(8):4042-5. PMID: 23689728; PMCID: PMC3719745.
      44. Vidaillac C, Gardete S, Tewhey R, Sakoulas G, Kaatz GW, Rose WE, Tomasz A, Rybak MJ. Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus. J Infect Dis. 2013 Jul; 208(1):67-74. PMID: 23539745; PMCID: PMC3666135.
      45. Werth BJ, Vidaillac C, Murray KP, Newton KL, Sakoulas G, Nonejuie P, Pogliano J, Rybak MJ. Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA. Antimicrob Agents Chemother. 2013 May; 57(5):2376-9. PMID: 23422917; PMCID: PMC3632910.
      46. Moise PA, Amodio-Groton M, Rashid M, Lamp KC, Hoffman-Roberts HL, Sakoulas G, Yoon MJ, Schweitzer S, Rastogi A. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant ß-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment. Antimicrob Agents Chemother. 2013 Mar; 57(3):1192-200. PMID: 23254428; PMCID: PMC3591880.
      47. Orsini J, Mainardi C, Muzylo E, Karki N, Cohen N, Sakoulas G. Microbiological profile of organisms causing bloodstream infection in critically ill patients. J Clin Med Res. 2012 Dec; 4(6):371-7. PMID: 23226169; PMCID: PMC3513418.
      48. Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2013 Jan; 57(1):66-73. PMID: 23070161; PMCID: PMC3535972.
      49. Haste NM, Thienphrapa W, Tran DN, Loesgen S, Sun P, Nam SJ, Jensen PR, Fenical W, Sakoulas G, Nizet V, Hensler ME. Activity of the thiopeptide antibiotic nosiheptide against contemporary strains of methicillin-resistant Staphylococcus aureus. J Antibiot (Tokyo). 2012 Dec; 65(12):593-8. PMID: 23047246; PMCID: PMC3528839.
      50. Rose WE, Eickhoff JC, Shukla SK, Pantrangi M, Rooijakkers S, Cosgrove SE, Nizet V, Sakoulas G. Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia. J Infect Dis. 2012 Nov 15; 206(10):1604-11. PMID: 22966128.
        View in: PubMed
      51. Humphries RM, Kelesidis T, Tewhey R, Rose WE, Schork N, Nizet V, Sakoulas G. Genotypic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 2012 Nov; 56(11):6051-3. PMID: 22948885; PMCID: PMC3486580.
      52. Mishra NN, Bayer AS, Moise PA, Yeaman MR, Sakoulas G. Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients. J Infect Dis. 2012 Oct; 206(8):1160-7. PMID: 22904338; PMCID: PMC3448966.
      53. Berti AD, Wergin JE, Girdaukas GG, Hetzel SJ, Sakoulas G, Rose WE. Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics. Antimicrob Agents Chemother. 2012 Oct; 56(10):5046-53. PMID: 22802248; PMCID: PMC3457407.
      54. Dhand A, Sakoulas G. Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC Creep'): implications for therapy. F1000 Med Rep. 2012; 4:4. PMID: 22312414; PMCID: PMC3270590.
      55. Sakoulas G, Nam SJ, Loesgen S, Fenical W, Jensen PR, Nizet V, Hensler M. Novel bacterial metabolite merochlorin A demonstrates in vitro activity against multi-drug resistant methicillin-resistant Staphylococcus aureus. PLoS One. 2012; 7(1):e29439. PMID: 22279537; PMCID: PMC3261149.
      56. McGillivray SM, Tran DN, Ramadoss NS, Alumasa JN, Okumura CY, Sakoulas G, Vaughn MM, Zhang DX, Keiler KC, Nizet V. Pharmacological inhibition of the ClpXP protease increases bacterial susceptibility to host cathelicidin antimicrobial peptides and cell envelope-active antibiotics. Antimicrob Agents Chemother. 2012 Apr; 56(4):1854-61. PMID: 22252821; PMCID: PMC3318395.
      57. Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN, Nizet V, Yeaman MR, Moise PA. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 2012 Feb; 56(2):838-44. PMID: 22123698; PMCID: PMC3264218.
      58. Schweizer ML, Furuno JP, Harris AD, Johnson JK, Shardell MD, McGregor JC, Thom KA, Cosgrove SE, Sakoulas G, Perencevich EN. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis. 2011 Oct 19; 11:279. PMID: 22011388; PMCID: PMC3206863.
      59. Pichereau S, Moran JJ, Hayney MS, Shukla SK, Sakoulas G, Rose WE. Concentration-dependent effects of antimicrobials on Staphylococcus aureus toxin-mediated cytokine production from peripheral blood mononuclear cells. J Antimicrob Chemother. 2012 Jan; 67(1):123-9. PMID: 21980070.
        View in: PubMed
      60. Walraven CJ, North MS, Marr-Lyon L, Deming P, Sakoulas G, Mercier RC. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2011 Oct; 66(10):2386-92. PMID: 21775337.
        View in: PubMed
      61. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, Wang G, Sakoulas G. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011 Jul 15; 53(2):158-63. PMID: 21690622; PMCID: PMC3697476.
      62. Kullar R, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy. 2011 Jun; 31(6):527-36. PMID: 21923436.
        View in: PubMed
      63. Fischer A, Yang SJ, Bayer AS, Vaezzadeh AR, Herzig S, Stenz L, Girard M, Sakoulas G, Scherl A, Yeaman MR, Proctor RA, Schrenzel J, François P. Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach. J Antimicrob Chemother. 2011 Aug; 66(8):1696-711. PMID: 21622973; PMCID: PMC3133485.
      64. Schweizer ML, Furuno JP, Sakoulas G, Johnson JK, Harris AD, Shardell MD, McGregor JC, Thom KA, Perencevich EN. Increased mortality with accessory gene regulator (agr) dysfunction in Staphylococcus aureus among bacteremic patients. Antimicrob Agents Chemother. 2011 Mar; 55(3):1082-7. PMID: 21173172; PMCID: PMC3067101.
      65. Le J, Bookstaver PB, Rudisill CN, Hashem MG, Iqbal R, James CL, Sakoulas G. Treatment of meningitis caused by vancomycin-resistant Enterococcus faecium: high-dose and combination daptomycin therapy. Ann Pharmacother. 2010 Dec; 44(12):2001-6. PMID: 21119097.
        View in: PubMed
      66. Seidl K, Bayer AS, Fowler VG, McKinnell JA, Abdel Hady W, Sakoulas G, Yeaman MR, Xiong YQ. Combinatorial phenotypic signatures distinguish persistent from resolving methicillin-resistant Staphylococcus aureus bacteremia isolates. Antimicrob Agents Chemother. 2011 Feb; 55(2):575-82. PMID: 21098242; PMCID: PMC3028773.
      67. Schweizer ML, Furuno JP, Harris AD, Johnson JK, Shardell MD, McGregor JC, Thom KA, Sakoulas G, Perencevich EN. Empiric antibiotic therapy for Staphylococcus aureus bacteremia may not reduce in-hospital mortality: a retrospective cohort study. PLoS One. 2010 Jul 02; 5(7):e11432. PMID: 20625395; PMCID: PMC2896397.
      68. Moise PA, Forrest A, Bayer AS, Xiong YQ, Yeaman MR, Sakoulas G. Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes. J Infect Dis. 2010 Jan 15; 201(2):233-40. PMID: 20001853; PMCID: PMC2819315.
      69. Yang SJ, Kreiswirth BN, Sakoulas G, Yeaman MR, Xiong YQ, Sawa A, Bayer AS. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis. 2009 Dec 15; 200(12):1916-20. PMID: 19919306; PMCID: PMC2779839.
      70. Sakoulas G. Clinical outcomes with daptomycin: a post-marketing, real-world evaluation. Clin Microbiol Infect. 2009 Dec; 15 Suppl 6:11-6. PMID: 19917022.
        View in: PubMed
      71. Wong A, Reddy SP, Smyth DS, Aguero-Rosenfeld ME, Sakoulas G, Robinson DA. Polyphyletic emergence of linezolid-resistant staphylococci in the United States. Antimicrob Agents Chemother. 2010 Feb; 54(2):742-8. PMID: 19933808; PMCID: PMC2812165.
      72. Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis. 2009 Oct; 9(10):617-24. PMID: 19778764.
        View in: PubMed
      73. Dandache P, Moise PA, Orsini J, Montecalvo M, Sakoulas G. Reduced biofilm production associated with increasing linezolid MICs among linezolid-resistant staphylococci. J Antimicrob Chemother. 2009 Nov; 64(5):1114-5. PMID: 19734169.
        View in: PubMed
      74. Sakoulas G, Brown J, Lamp KC, Friedrich LV, Lindfield KC. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience. Clin Ther. 2009 Sep; 31(9):1936-45. PMID: 19843483.
        View in: PubMed
      75. Sakoulas G, Wormser GP, Visintainer P, Aronow WS, Nadelman RB. Relationship between population density of attorneys and prevalence of methicillin-resistant Staphylococcus aureus: is medical-legal pressure on physicians a driving force behind the development of antibiotic resistance? Am J Ther. 2009 Sep-Oct; 16(5):e1-6. PMID: 19955854.
        View in: PubMed
      76. LaPlante KL, Sakoulas G. Evaluating aztreonam and ceftazidime pharmacodynamics with Escherichia coli in combination with daptomycin, linezolid, or vancomycin in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2009 Oct; 53(10):4549-55. PMID: 19620335; PMCID: PMC2764192.
      77. Harigaya Y, Bulitta JB, Forrest A, Sakoulas G, Lesse AJ, Mylotte JM, Tsuji BT. Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia. Antimicrob Agents Chemother. 2009 Sep; 53(9):3894-901. PMID: 19596879; PMCID: PMC2737835.
      78. Sakoulas G, Moise PA, Rybak MJ. Accessory gene regulator dysfunction: an advantage for Staphylococcus aureus in health-care settings? J Infect Dis. 2009 May 15; 199(10):1558-9. PMID: 19392634.
        View in: PubMed
      79. Tsuji BT, Harigaya Y, Lesse AJ, Sakoulas G, Mylotte JM. Loss of vancomycin bactericidal activity against accessory gene regulator (agr) dysfunctional Staphylococcus aureus under conditions of high bacterial density. Diagn Microbiol Infect Dis. 2009 Jun; 64(2):220-4. PMID: 19345040.
        View in: PubMed
      80. Moise PA, Smyth DS, Robinson DA, El-Fawal N, McCalla C, Sakoulas G. Genotypic and phenotypic relationships among methicillin-resistant Staphylococcus aureus from three multicentre bacteraemia studies. J Antimicrob Chemother. 2009 May; 63(5):873-6. PMID: 19261624; PMCID: PMC2667134.
      81. Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother. 2009 Feb; 53(2):483-6. PMID: 19001107; PMCID: PMC2630630.
      82. Sakoulas G. Daptomycin for soft tissue infection and neutropenia in a myelogenous leukemia patient who failed prior vancomycin therapy. Clin Adv Hematol Oncol. 2008 Nov; 6(11):813-5. PMID: 19194364.
        View in: PubMed
      83. Orsini J, Nowakowski J, Delaney V, Sakoulas G, Wormser GP. Cryptococcal infection presenting as cellulitis in a renal transplant recipient. Transpl Infect Dis. 2009 Feb; 11(1):68-71. PMID: 19000155.
        View in: PubMed
      84. McCalla C, Smyth DS, Robinson DA, Steenbergen J, Luperchio SA, Moise PA, Fowler VG, Sakoulas G. Microbiological and genotypic analysis of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2008 Sep; 52(9):3441-3. PMID: 18606839; PMCID: PMC2533503.
      85. Lalani T, Federspiel JJ, Boucher HW, Rude TH, Bae IG, Rybak MJ, Tonthat GT, Corey GR, Stryjewski ME, Sakoulas G, Chu VH, Alder J, Steenbergen JN, Luperchio SA, Campion M, Woods CW, Fowler VG. Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients. J Clin Microbiol. 2008 Sep; 46(9):2890-6. PMID: 18596141; PMCID: PMC2546778.
      86. Gqada Z, Marais B, Wasserman E, Bamford C, Orth H, Sakoulas G, Rose W, Rybak MJ, Pillai S, Alder J, Moellering RC, Eliopoulos GM. Clinical rationale for treatment of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. J Clin Microbiol. 2008 Jul; 46(7):2471; author reply 2471-2. PMID: 18614667; PMCID: PMC2446886.
      87. Sakoulas G, Moellering RC. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis. 2008 Jun 01; 46 Suppl 5:S360-7. PMID: 18462091.
        View in: PubMed
      88. Moise PA, Castro RS, Sul C, Forrest A, Sakoulas G. Relationship of linezolid minimum inhibitory concentration and time to bacterial eradication in treatment for methicillin-resistant Staphylococcus aureus infection. Ann Pharmacother. 2008 Apr; 42(4):592-3. PMID: 18349303.
        View in: PubMed
      89. Rose WE, Kaatz GW, Sakoulas G, Rybak MJ. Teicoplanin pharmacodynamics in reference to the accessory gene regulator (agr) in Staphylococcus aureus using an in vitro pharmacodynamic model. J Antimicrob Chemother. 2008 May; 61(5):1099-102. PMID: 18263568.
        View in: PubMed
      90. Moise PA, Smyth DS, El-Fawal N, Robinson DA, Holden PN, Forrest A, Sakoulas G. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2008 Jan; 61(1):85-90. PMID: 18042628.
        View in: PubMed
      91. Sakoulas G, Rose W, Rybak MJ, Pillai S, Alder J, Moellering RC, Eliopoulos GM. Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. J Clin Microbiol. 2008 Jan; 46(1):220-4. PMID: 18003803; PMCID: PMC2224245.
      92. Rose WE, Leonard SN, Sakoulas G, Kaatz GW, Zervos MJ, Sheth A, Carpenter CF, Rybak MJ. daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2008 Mar; 52(3):831-6. PMID: 17999971; PMCID: PMC2258488.
      93. Jones T, Yeaman MR, Sakoulas G, Yang SJ, Proctor RA, Sahl HG, Schrenzel J, Xiong YQ, Bayer AS. Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother. 2008 Jan; 52(1):269-78. PMID: 17954690; PMCID: PMC2223911.
      94. Sakoulas G, Golan Y, Lamp KC, Friedrich LV, Russo R. Daptomycin in the treatment of bacteremia. Am J Med. 2007 Oct; 120(10 Suppl 1):S21-7. PMID: 17904947.
        View in: PubMed
      95. Boucher HW, Sakoulas G. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis. 2007 Sep 01; 45(5):601-8. PMID: 17682996.
        View in: PubMed
      96. Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2007 Jul; 51(7):2582-6. PMID: 17452488; PMCID: PMC1913284.
      97. Rose WE, Rybak MJ, Tsuji BT, Kaatz GW, Sakoulas G. Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function. J Antimicrob Chemother. 2007 Jun; 59(6):1190-3. PMID: 17434881.
        View in: PubMed
      98. Pillai SK, Gold HS, Sakoulas G, Wennersten C, Moellering RC, Eliopoulos GM. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob Agents Chemother. 2007 Jun; 51(6):2223-5. PMID: 17404001; PMCID: PMC1891363.
      99. Dandache P, Aronow WS, Sakoulas G. Clinical update on the diagnosis and treatment of bacterial endocarditis. Compr Ther. 2007; 33(4):192-207. PMID: 18025611.
        View in: PubMed
      100. Tsuji BT, Rybak MJ, Lau KL, Sakoulas G. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2007 Mar; 51(3):1089-91. PMID: 17158941; PMCID: PMC1803123.
      101. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother. 2006 Apr; 50(4):1581-5. PMID: 16569891; PMCID: PMC1426932.
      102. Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother. 2006 Apr; 57(4):699-704. PMID: 16464892.
        View in: PubMed
      103. Sakoulas G, Moellering RC, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis. 2006 Jan 01; 42 Suppl 1:S40-50. PMID: 16323119.
        View in: PubMed
      104. Sakoulas G, Eliopoulos GM, Fowler VG, Moellering RC, Novick RP, Lucindo N, Yeaman MR, Bayer AS. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother. 2005 Jul; 49(7):2687-92. PMID: 15980337; PMCID: PMC1168700.
      105. Fowler VG, Sakoulas G, McIntyre LM, Meka VG, Arbeit RD, Cabell CH, Stryjewski ME, Eliopoulos GM, Reller LB, Corey GR, Jones T, Lucindo N, Yeaman MR, Bayer AS. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis. 2004 Sep 15; 190(6):1140-9. PMID: 15319865.
        View in: PubMed
      106. Pillai SK, Sakoulas G, Eliopoulos GM, Moellering RC, Murray BE, Inouye RT. Effects of glucose on fsr-mediated biofilm formation in Enterococcus faecalis. J Infect Dis. 2004 Sep 01; 190(5):967-70. PMID: 15295702.
        View in: PubMed
      107. Meka VG, Pillai SK, Sakoulas G, Wennersten C, Venkataraman L, DeGirolami PC, Eliopoulos GM, Moellering RC, Gold HS. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis. 2004 Jul 15; 190(2):311-7. PMID: 15216466.
        View in: PubMed
      108. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004 Jun; 42(6):2398-402. PMID: 15184410; PMCID: PMC427878.
      109. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis. 2004 Jun 15; 38(12):1700-5. PMID: 15227615.
        View in: PubMed
      110. Tarr PE, Sakoulas G, Ganesan A, Smith MA, Lucey DR. Hematogenous enterococcal vertebral osteomyelitis: report of 2 cases and review of the literature. J Infect. 2004 May; 48(4):354-62. PMID: 15066338.
        View in: PubMed
      111. Woods CW, Cheng AC, Fowler VG, Moorefield M, Frederick J, Sakoulas G, Meka VG, Tenover FC, Zwadyk P, Wilson KH. Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis. 2004 Apr 15; 38(8):1188-91. PMID: 15095227.
        View in: PubMed
      112. Schwaber MJ, Wright SB, Carmeli Y, Venkataraman L, DeGirolami PC, Gramatikova A, Perl TM, Sakoulas G, Gold HS. Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. Emerg Infect Dis. 2003 Jun; 9(6):657-64. PMID: 12781004; PMCID: PMC3000153.
      113. Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003 May; 47(5):1714-8. PMID: 12709345; PMCID: PMC153308.
      114. Sakoulas G, Gold HS, Venkataraman L, Moellering RC, Ferraro MJ, Eliopoulos GM. Introduction of erm(C) into a linezolid- and methicillin-resistant Staphylococcus aureus does not restore linezolid susceptibility. J Antimicrob Chemother. 2003 Apr; 51(4):1039-41. PMID: 12728937.
        View in: PubMed
      115. Sakoulas G, Eliopoulos GM, Moellering RC, Novick RP, Venkataraman L, Wennersten C, DeGirolami PC, Schwaber MJ, Gold HS. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis. 2003 Mar 15; 187(6):929-38. PMID: 12660939.
        View in: PubMed
      116. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003 Jan 01; 36(1):53-9. PMID: 12491202.
        View in: PubMed
      117. Pillai SK, Sakoulas G, Wennersten C, Eliopoulos GM, Moellering RC, Ferraro MJ, Gold HS. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J Infect Dis. 2002 Dec 01; 186(11):1603-7. PMID: 12447736.
        View in: PubMed
      118. Pillai SK, Sakoulas G, Gold HS, Wennersten C, Eliopoulos GM, Moellering RC, Inouye RT. Prevalence of the fsr locus in Enterococcus faecalis infections. J Clin Microbiol. 2002 Jul; 40(7):2651-2. PMID: 12089299; PMCID: PMC120556.
      119. Sakoulas G, Eliopoulos GM, Moellering RC, Wennersten C, Venkataraman L, Novick RP, Gold HS. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother. 2002 May; 46(5):1492-502. PMID: 11959587; PMCID: PMC127153.
      120. Sakoulas G, Gold HS, Venkataraman L, DeGirolami PC, Eliopoulos GM, Qian Q. Methicillin-resistant Staphylococcus aureus: comparison of susceptibility testing methods and analysis of mecA-positive susceptible strains. J Clin Microbiol. 2001 Nov; 39(11):3946-51. PMID: 11682512; PMCID: PMC88469.
      121. Petrogiannis-Haliotis T, Sakoulas G, Kirby J, Koralnik IJ, Dvorak AM, Monahan-Earley R, DE Girolami PC, DE Girolami U, Upton M, Major EO, Pfister LA, Joseph JT. BK-related polyomavirus vasculopathy in a renal-transplant recipient. N Engl J Med. 2001 Oct 25; 345(17):1250-5. PMID: 11680445.
        View in: PubMed
      122. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, Moellering RC, Ferraro MJ. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001 Jul 21; 358(9277):207-8. PMID: 11476839.
        View in: PubMed
      123. Sakoulas G, Degirolami PC, Gold HS. Methicillin-susceptible Staphylococcus aureus: believe it, or not. Arch Intern Med. 2001 May 14; 161(9):1237-8. PMID: 11343454.
        View in: PubMed
      124. Sakoulas G. Brainstem and striatal encephalitis complicating Mycoplasma pneumoniae pneumonia: possible benefit of intravenous immunoglobulin. Pediatr Infect Dis J. 2001 May; 20(5):543-5. PMID: 11368117.
        View in: PubMed
      125. Ross MJ, Sakoulas G, Manning WJ, Cohn WE, Lisbon A. Corynebacterium jeikeium native valve endocarditis following femoral access for coronary angiography. Clin Infect Dis. 2001 Apr 01; 32(7):E120-1. PMID: 11264050.
        View in: PubMed
      126. Sakoulas G, Anastopoulos H. Successful use of cyclosporine in the treatment of glucocorticoid- resistant nongranulomatous chronic idiopathic enterocolitis. Gastroenterology. 1999 Nov; 117(5):1259-60. PMID: 10610339.
        View in: PubMed
      127. Sakoulas G, Tritos NA, Lally M, Wanke C, Hartzband P. Hypercalcemia in an AIDS patient treated with growth hormone. AIDS. 1997 Sep; 11(11):1353-6. PMID: 9302445.
        View in: PubMed
      128. Sándor Z, Kusstatscher S, Sakoulas G, Szabó S. [Role of endogenous basic fibroblast growth factor in experimental duodenal ulcer]. Orv Hetil. 1995 Jul 09; 136(28):1501-3. PMID: 7637967.
        View in: PubMed
      129. Szabo S, Kusstatscher S, Sandor Z, Sakoulas G. Molecular and cellular basis of ulcer healing. Scand J Gastroenterol Suppl. 1995; 208:3-8. PMID: 7777801.
        View in: PubMed
      130. Szabo S, Kusstatscher S, Sakoulas G, Sandor Z, Vincze A, Jadus M. Growth factors: new 'endogenous drugs' for ulcer healing. Scand J Gastroenterol Suppl. 1995; 210:15-8. PMID: 8578198.
        View in: PubMed
      131. Colón-Teicher L, Wise LS, Martino JJ, Baskin L, Sakoulas G, Pollack RE, Chen S. Genomic sequences capable of committing mouse and rat fibroblasts to adipogenesis. Nucleic Acids Res. 1993 May 11; 21(9):2223-8. PMID: 8502564; PMCID: PMC309488.
      132. Fukasawa K, Sakoulas G, Pollack RE, Chen S. Excess wild-type p53 blocks initiation and maintenance of simian virus 40 transformation. Mol Cell Biol. 1991 Jul; 11(7):3472-83. PMID: 1646391; PMCID: PMC361080.
      George's Networks
      Derived automatically from this person's publications.
      People in Profiles who have published with this person.
      Similar People
      People who share similar concepts with this person.
      Same Department
      Physical Neighbors
      People whose addresses are nearby this person.